EP3342411

NOVARTIS AG
Application Number
EP18155724A
Filing Date
Feb 18, 2002
Status
Opposition Rejected
Dec 18, 2023
Grant Date
Aug 21, 2019
External Links
Slate, Register

Biblio Summary

The patent EP3342411B1 was granted on Aug 21, 2019 by Novartis Ag The patent is currently Opposition Rejected.

The table below shows 10 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ARROW GENERIQUESJun 1, 2020ADMISSIBLE
TEVAMay 19, 2020ADMISSIBLE
ZENTIVA K.S.May 11, 2020ADMISSIBLE
GENERICS UKMay 5, 2020WITHDRAWN
PUREN PHARMA GMBH & CO. KGApr 29, 2020WITHDRAWN
ETHYPHARMFeb 14, 2020ADMISSIBLE
BIOGARANSep 30, 2019ADMISSIBLE
DR. REDDY'S LABORATORIES LTD./ BETAPHARM ARZNEIMITTEL GMBHAug 27, 2019WITHDRAWN
ACCORD HEALTHCARE LTDAug 23, 2019WITHDRAWN
STADAAug 22, 2019ADMISSIBLE

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245